Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alendronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 16/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alendronic Acid SCHEMBL6270347 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL1115700 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL167772 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL140618 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14645374 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL19614558 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL14645375 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL579001 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4646147 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL4284352 | 0.98 | FDPS (0.95) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 41820 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746914-A1 | DRUG CONJUGATES FOR BONE MARROW PROTECTION | Zymeron Corporation (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3727367-B1 | VITAMIN K2 COMPOSITIONS FOR USE IN THE TREATMENT OF DRUG INDUCED NEUROPATHY | SYNERGIA LIFE SCIENCES PVT LTD (IN) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-121755170-B | Organic phosphine modified bio-based rare earth adsorption material and preparation method and application thereof | WUHAN INSTITUTE OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122075784-A | Bionic bone with controllable solidification time and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075712-A | Antitumor composition of engineering bacteria and bisphosphonate compounds for expressing hemolysin and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137780-A1 | MATERIALS AND METHODS FOR IMPROVED EXPANSION AND USES OF IMMUNE CELLS | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | claimed |
| EP-0402152-A2 | Crystalline 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid monosodium trihydrate, process therefor and compositions and use thereof | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | claimed |
| US-4922007-A | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof | MERCK & CO., INC. (US) | 1990-05-01 | — | — | US | claimed |
| WO-1989007453-A1 | MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-08-24 | — | — | WO | claimed |
| US-4814326-A | Pharmaceutical compositions based on diphosphonates for the treatment of arthrosis and osteoarthritis | ISTITUTO GENTILI S.P.A. (IT) | 1989-03-21 | — | — | US | claimed |
| EP-0276288-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BISPHOSPHONATE AND THEIR USE FOR NASAL ADMINISTRATION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1988-08-03 | — | — | EP | claimed |
| WO-1988000829-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BISPHOSPHONATE AND THEIR USE FOR NASAL ADMINISTRATION | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1988-02-11 | — | — | WO | claimed |
| US-4705651-A | Process for the preparation of diphosphonic acids | ISTITUTO GENTILI S.P.A. (IT) | 1987-11-10 | — | — | US | claimed |
| EP-0203649-A2 | Pharmaceutic composition based on diphoshonates for the treatment of the arthrosis | ISTITUTO GENTILI S.p.A. (IT) | 1986-12-03 | — | — | EP | claimed |
| US-4621077-A | Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom | ISTITUTO GENTILI S.P.A. (IT) | 1986-11-04 | — | — | US | claimed |
| CN-85100618-A | Preventing fouling of turbine blades for differential pressure power generation | — | 1986-10-01 | — | — | CN | claimed |